(19S)-19-methyl-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡喃吡啶类
• 英文名称: (19S)-19-methyl-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione
• 化学式: C₁₉H₁₄N₂O₃
• 分子量: 318.3
• InChiKey: PPOPQRZJHWVUHD-JTQLQIEISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  24
• 可旋转键数：
  0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  59.5
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• NANOPARTICLES STABILIZED WITH NITROPHENYLBORONIC ACID COMPOSITIONS
  申请人：CALIFORNIA INSTITUTE OF TECHNOLOGY

  公开号：US20140249203A1

  公开（公告）日：2014-09-04

  Described herein are carrier nanoparticles comprising a polymer containing a polyol coupled to a polymer containing a boronic acid, configured to present the polymer containing a boronic acid to an environment external to the nanoparticle. Targeted versions of the described nanoparticles are also described, as are related compositions, methods and systems.

  本文描述了一种载体纳米颗粒，其中包含一个含有多元醇的聚合物和一个含有硼酸的聚合物，设计用于将含有硼酸的聚合物呈现给纳米颗粒外部的环境。还描述了所述纳米颗粒的定向版本，以及相关的组合物、方法和系统。
• CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING COVALENTLY ATTACHED CAMPTOTHECIN
  申请人：Cerulean Pharma Inc.

  公开号：EP3332811A1

  公开（公告）日：2018-06-13

  The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.

  本发明涉及治疗用环糊精高分子化合物的新型组合物，该组合物被设计为小分子治疗剂输送的载体及其药物组合物。这些含环糊精的聚合物可提高药物的稳定性和溶解度，降低小分子治疗药物在体内使用时的毒性。此外，通过从各种连接基团和靶向配体中进行选择，这些聚合物还提供了治疗剂的控制输送方法。本发明还涉及用本文所述治疗组合物治疗受试者的方法。本发明还涉及开展制药业务的方法，包括制造、许可或分销含有或与本文所述聚合物化合物有关的试剂盒。
• PREPARATION PROCESS OF PSMA BINDING LIGAND-LINKER CONJUGATES
  申请人：Purdue Research Foundation

  公开号：EP3656403A1

  公开（公告）日：2020-05-27

  Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.

  本文描述的是前列腺特异性膜抗原（PSMA）结合共轭物，可用于递送治疗、诊断和成像制剂。本文还描述了含有它们的药物组合物以及使用这些共轭物和组合物的方法。还描述了共轭物和含有共轭物的组合物的制造工艺。
• CARRIER NANOPARTICLES AND RELATED COMPOSITIONS, METHODS AND SYSTEMS
  申请人：CALIFORNIA INSTITUTE OF TECHNOLOGY

  公开号：US20170080099A1

  公开（公告）日：2017-03-23

  Carrier nanoparticles comprising a polymer containing a polyol coupled to a polymer containing a boronic acid and a linkage cleavable under reducing conditions, configured to present the polymer containing a boronic acid to an environment external to the nanoparticle and related compositions, methods and systems.
• US9132097B2
  申请人：——

  公开号：US9132097B2

  公开（公告）日：2015-09-15